| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1998) |
| Entry Type: | Small molecule |
| Molecule Category: | Salt |
| UNII: | GLS2PGI8QG |
| Parent Compound: | SEVELAMER |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| SEQUESTERING AGENT | Phosphate sequestering agent |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Transferase
|
- | - | - | - | ||
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | - | - | - | -4.03--0.58 |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Kidney Diseases | 4 | D007674 | FDA |
| Hyperphosphatemia | 4 | D054559 | ClinicalTrials |
| Kidney Failure, Chronic | 3 | D007676 | ClinicalTrials |
| Hypercholesterolemia | 2 | D006937 | ClinicalTrials |
| Chronic Kidney Disease-Mineral and Bone Disorder | 2 | D012080 | ClinicalTrials |
| Hyperparathyroidism, Secondary | 2 | D006962 | ClinicalTrials |
Related Entries
Adverse Reactions
System Organ Classification (SOC)
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL1201492 |
| FDA SRS | GLS2PGI8QG |
CONTENTS